What was the average weight loss achieved by ribupatide in the China study?

In the 26-week mid-stage study in China, patients on 25-mg and 50-mg doses of ribupatide achieved a mean weight loss of 12.1%.

What side effects were reported for the experimental obesity drug ribupatide?

The most common side effects related to ribupatide were mild to moderate nausea, vomiting, diarrhea, and constipation.

What are the next steps for the obesity drug ribupatide?

Hengrui will conduct a late-stage obesity trial in China, while Kailera plans to begin a global mid-stage trial this year. An injectable version is also in late-stage global evaluation.

Home / Health / Obesity Pill Shows Promising Weight Loss in China Study

Obesity Pill Shows Promising Weight Loss in China Study

10 Feb

•

Summary

Experimental obesity drug led to up to 12.1% body weight loss.
The drug belongs to the GLP-1 class, similar to other popular treatments.
Most side effects were mild, with no treatment discontinuations reported.

Obesity Pill Shows Promising Weight Loss in China Study

In a mid-stage study conducted in China, an experimental oral obesity drug, ribupatide, demonstrated significant weight loss results. Developed by U.S.-based Kailera Therapeutics and its partner Jiangsu Hengrui Pharmaceuticals, the once-daily pill helped patients lose up to 12.1% of their body weight over 26 weeks. This drug is part of the GLP-1 class, which includes well-known treatments for weight management, though ribupatide employs a distinct approach.

The 166-participant study indicated that doses of 25-mg and 50-mg resulted in a mean weight loss of 12.1%, compared to a 6.9% loss for the 10-mg dose against a placebo. The companies reported that common side effects, such as nausea and diarrhea, were generally mild to moderate. Crucially, no participants ceased treatment or required a dose reduction due to adverse events.